Altimmune, Inc. (NASDAQ:ALT - Get Free Report)'s stock price dropped 5.2% during mid-day trading on Monday . The company traded as low as $8.60 and last traded at $8.62. Approximately 302,297 shares changed hands during trading, a decline of 95% from the average daily volume of 5,786,986 shares. The stock had previously closed at $9.09.
Wall Street Analyst Weigh In
Several research firms have recently weighed in on ALT. HC Wainwright decreased their price objective on shares of Altimmune from $15.00 to $12.00 and set a "buy" rating for the company in a report on Monday, April 1st. The Goldman Sachs Group initiated coverage on Altimmune in a report on Wednesday, January 24th. They set a "neutral" rating and a $13.00 price target on the stock. Finally, B. Riley restated a "buy" rating and issued a $20.00 price target on shares of Altimmune in a research note on Thursday, March 28th.
View Our Latest Research Report on ALT
Altimmune Stock Performance
The company's 50-day moving average price is $9.90 and its 200 day moving average price is $7.06. The stock has a market cap of $610.36 million, a PE ratio of -5.22 and a beta of 0.05.
Institutional Investors Weigh In On Altimmune
A number of hedge funds have recently modified their holdings of the business. BlackRock Inc. boosted its position in shares of Altimmune by 162.9% in the second quarter. BlackRock Inc. now owns 3,664,274 shares of the company's stock worth $12,935,000 after purchasing an additional 2,270,219 shares during the period. Vanguard Group Inc. boosted its holdings in Altimmune by 6.8% in the 4th quarter. Vanguard Group Inc. now owns 3,571,972 shares of the company's stock worth $40,185,000 after buying an additional 227,677 shares during the period. Nuveen Asset Management LLC increased its stake in Altimmune by 5.8% in the 2nd quarter. Nuveen Asset Management LLC now owns 3,458,949 shares of the company's stock worth $12,210,000 after buying an additional 190,888 shares in the last quarter. State Street Corp raised its holdings in Altimmune by 2,407.5% during the third quarter. State Street Corp now owns 3,398,856 shares of the company's stock valued at $43,403,000 after acquiring an additional 3,263,310 shares during the period. Finally, Marshall Wace LLP lifted its position in shares of Altimmune by 28.9% in the second quarter. Marshall Wace LLP now owns 2,059,290 shares of the company's stock valued at $7,269,000 after acquiring an additional 462,160 shares in the last quarter. Institutional investors own 78.05% of the company's stock.
About Altimmune
(
Get Free Report)
Altimmune, Inc, a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. The company's lead product candidate, pemvidutide, a GLP-1/glucagon dual receptor agonist that is in Phase 2 trial for the treatment of obesity and non-alcoholic steatohepatitis.
Further Reading
Before you consider Altimmune, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Altimmune wasn't on the list.
While Altimmune currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know?
Get This Free Report
